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Abstract
Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4
(HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-a (IFNa) treatment for
HCV may trigger serum autoantibodies against pancreatic islet cells (ICA) in a subgroup of patients. Available data on the
incidence of ICA during IFNa therapy for chronic HCV4 infection are not conclusive. We investigated the appearance of ICA
in 40 naı ¨ve Egyptian patients (38 males, 32 ^ 6 years) with histologically deﬁned chronic HCV4 infection undergoing IFNa
treatment at a dose of 9-million U/week for 24 weeks. Serum samples were collected at baseline and following IFNa therapy
and ICA were detected using indirect immunoﬂuorescence. Baseline evaluation indicated that 2/40 (5%) patients had
detectable serum ICA. After the completion of the treatment scheme, 12/38 (32%) previously ICA negative patients became
ICA positive; however, no patient developed impaired glucose tolerance (IGT) or diabetes during follow-up. In conclusion,
we submit that IFNa treatment for chronic hepatitis C (CHC) may induce serum ICA in one-third of Egyptian patients
with HCV4. These autoantibodies, however, do not lead to alterations in glucose metabolism.
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Introduction
Hepatitis C virus (HCV) infection is a leading cause of
chronichepatitisandithasbeenestimatedtoaffect170
million people worldwide (Lauer and Walker 2001).
Prevalence rates for serum anti-HCV positivity in the
general population range between 1% in North
America (Alter 1997) to over 20% in endemic areas
such as Egypt (Abdel-Aziz et al. 2000). Acute HCV
infectionleadstochronichepatitisC(CHC)inthevast
majority of cases thus increasing the risk of developing
cirrhosis and eventually hepatocellular carcinoma
(Alter and Seeff 2000, Liang et al. 2000). Six major
HCV genotypes are known (Hoofnagle 2002) and
signiﬁcantly differ in their geographical distribution.
HCVgenotype4(HCV4)ispredominantinAfricaand
the Middle East (McOmish et al. 1994) and is
responsible for over 90% of infection cases in Egypt
(Rayet al. 2000) while being rare in western countries.
Treatment regimens for CHC are based on
interferon-a (IFNa) molecules usually in combination
with ribavirin (Ahmed and Keeffe 1999). Standard
dosing of non-pegylated IFNa molecules is 3 million
U three times a week and were commonly used in
Egypt until few years ago when validation of results
with pegylated IFNa became available (Zeuzem et al.
2000). In all cases, however, IFNa is administered
with ribavirin at daily doses of 1000/1200mg. In
2–10% of cases, IFNa side effects may lead to dose
modulation or cessation of therapy (Dusheiko 1997).
Among serious side effects related to IFNa therapy,
new-onset autoimmune manifestations are important
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disappear after IFNa withdrawal. Such manifestations
include the de novo appearance of serum autoanti-
bodies against thyroid antigens (Kiehne et al. 1997) or
pancreatic islet cells (ICA) (Wesche et al. 2001). The
latter are particularly important since they signiﬁ-
cantly correlate with the onset of impaired glucose
tolerance (IGT) or frank Diabetes mellitus (DM)
(Batstra et al. 2001).
Data on ICA incidence in patients with HCV4
chronic infection undergoing IFNa treatment are not
available. We herein report a serological study on 40
Egyptian patients with histologically deﬁned CHC
from HCV4 to deﬁne the risk in this subgroup of
patients to develop serum ICA and/or IGT/DM
during antiviral treatment.
Materials and methods
Subjects
We studied 40 patients (38 males, mean ^ SD age
32 ^ 6 years, range 24–52) with chronic HCV4
infection attending the outpatient clinic of the
National Liver Institute at Minuﬁya University.
Patients fulﬁlling the criteria for CHC diagnosis and
treatment eligibility were consecutively enrolled
between January 2002 and December 2003. The
diagnosis of CHC was based on positive serum anti-
HCV antibodies (Ortho Diagnostic Systems Inc.,
Raritan, NJ), positive serum HCV–RNA (Roche
Molecular Systems, Inc., Pleasanton, CA) and by liver
histology. All patients had HCV4. All patients had
undergone a liver biopsy within 12 months prior to
enrollment and histological features were consistent
with the diagnosis of CHC (Gerber 1997). Fibrosis or
cirrhosis was found in 20/40 (50%) cases. Patients
with clinical signs and symptoms of decompensated
cirrhosis (i.e. history of digestive bleeding from portal
hypertension, ascites, jaundice or hepatic encephalo-
pathy) were excluded from the study. No patient had
been previously been treated with IFN for CHC.
Serum samples were obtained after overnight fasting
before the beginning of treatment (baseline) as well as
after 12 weeks of therapy and 24 weeks after treatment
discontinuation for determination of ICA status. Sera
werestoredat2808untiluse.Serumglucoselevelsafter
overnight fasting (FGL) and 2h after a glucose load
(PPGL) were determined at baseline and at week 24
usingroutinetechniques.Thestudyprotocolrespected
the most recent Declaration of Helsinki (Edinburgh
2000), and all of the patients gave consent to the use of
their sera and clinical data for research purposes after
being informed about the nature of the study.
Antiviral treatment
Forty patients were enrolled in the study and
completed the six-month treatment. Twenty-four/40
(60%) and 16/40 (40%) patients were treated with
recombinant IFNa–2b and IFNa–2a, respectively. In
both groups, the dose was 3 million U subcutaneously
three times a week and all patients also received a
1000/1200mg daily dose of ribavirin. Treatment was
discontinued after 24 weeks in all cases.
ICA detection
Serum ICA were tested using indirect immunoﬂuor-
escence on monkey pancreatic cells following the
manufacturer’s protocol (Biosystems, Barcelona,
Spain). Sera showing light homogenous ﬂuorescence
in the cytoplasm of pancreatic islet cells were
considered positive.
Statistical analysis
Statistical analysis was performed using the Wilcoxon
rank sum test for comparison of non-parametric
variables and the McNemar test for the comparison of
dichotomous variables. P values ,0.05 were con-
sideredasstatisticallysigniﬁcant.Allcomparisonswere
performed using SPSS v11 (SPSS Inc., Chicago, IL).
Results
Response to treatment
Table I summarizes the biochemical characteristics
ofpatientsatenrollmentandfollowingantiviraltreatment.
Table I. Biochemical characteristics of patients with CHC before and after antiviral treatment.
Before treatment After treatment P value
Alanine aminotransferase (UI/l) 90 ^ 23 47 ^ 29 ,0.01
Aspartate aminotransferase (UI/l) 66 ^ 13 36 ^ 22 ,0.01
Total bilirubin (g/dl) 1.28 ^ 0.41 0.99 ^ 0.25 ,0.05
White blood cells (/ml) 6626 ^ 1086 5563 ^ 0,865 ,0.01
Platelets (/ml( £ 10
3) 246 ^ 51 196 ^ 57 ,0.05
Hemoglobin (g/dl) 12.9 ^ 0.6 11.1 ^ 0.5 ,0.01
HCV–RNA positive (n) 40/40 (100%) 10/40 (25%) ,0.01
Fasting glucose level (mg/dl) 87 ^ 10 88 ^ 7N S
Post prandial glucose level (mg/dl) 100 ^ 8 103 ^ 11 NS
Continuous variables are expressed as mean ^standard deviation; NS, non signiﬁcant
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blood cell (WBC) and platelet counts, hemoglobin
concentration, alanine (ALT) and aspartate (AST)
aminotransferase, total bilirubin and albumin serum
levels, and prothrombin time following IFNa þ ribavirin
therapy. Fasting and post-prandial blood glucose levels
did not change signiﬁcantly after treatment (87 ^ 10 vs
88 ^ 7mg/dl and 100 ^ 8 vs 103 ^ 11mg/dl, respect-
ively; P ¼ non-signiﬁcant for both comparisons). Serum
HCV–RNAbecameundetectableattheendoftreatment
in 10/40 (25%) patients following 24 weeks of therapy.
Serum ICA
Testing of ICA was carried out before treatment and 6
months after completion of therapy using indirect
immunoﬂuorescence; Figure 1 shows a representative
positive serum pattern. Table II illustrates the changes
of ICA positivity with treatment. Before antiviral
therapy, only 2/40 (5%) patients were positive had
detectable serum ICA and in both cases such reactivity
was still found following antiviral treatment. Thirty-
eight/40 (95%) patients were ICA-negative at baseline
and 12/38 (32%) developed serum ICA at the end of
treatment.
Glucose levels in serum ICA-based subgroups
Table III illustrates fasting and post-prandial glucose
levels in patients who developed serum ICA during
antiviral treatment. We failed to observe signiﬁcant
changes in fasting (86 ^ 13mg/dl before treatment
vs 86 ^ 6mg/dl after treatment; P ¼ NS) or post-
prandial (100 ^ 8mg/dl before treatment vs
106 ^ 14mg/dl after treatment; P ¼ NS) glucose
levels in the 12 patients who became serum ICA-
positive after therapy with IFNa þ ribavirin.
Importantly, none of these patient developed IGT or
DM. We also note that we failed to observe signiﬁcant
clinical or biochemical differences when patients were
subdivided based on the post-treatment serum ICA
status (data not shown).
Discussion
Antiviral treatments are being commonly used world-
wide for CHC (EASL International Consensus
Conference on Hepatitis C. Paris, 26–28, February
1999, Consensus Statement. European Association
for the Study of the Liver 1999), thus making the
deﬁnition of potential side effects a critical issue
(Dusheiko 1997). The vast majority of available data,
however, are based on patient series for Western
Countries, thus possibly being poorly representative of
other geographical areas where other HCV genotypes
are predominant, as is the case for HCV4 in Egypt
(Ray et al. 2000). We therefore investigated for the
ﬁrst time the effects of an IFNa-based antiviral
treatment on serum ICA and glucose metabolism in
patients with HCV4 chronic hepatitis. We report
herein that despite a 30% incidence of serum ICA
during a six-month treatment of IFNa and ribavirin,
Egyptian patients with HCV4 chronic infection do not
develop IGTor DM. We are aware that non-pegylated
IFNa is currently no longer the ﬁrst-line treatment of
choice for CHC; however, we submit that it was still
used at the time of patient enrollment in our center
and believe that observations obtained with such
treatment provide a good indication of potential side
effects to be expected with the newer pegylated
molecules.
Chronic HCV infection is a major cause of liver-
related morbidity and mortality worldwide (Shepard
et al. 2005). Current treatments based on IFNa
induce a sustained virological response in 40–67% of
patients (Teoh and Farrell 2004) but fail to clear the
virus in a sustained fashion in a signiﬁcant proportion
of cases and are burdened by signiﬁcant side effects.
Moreover, the complexity related to the geographical
distribution of HCV genotypes easily underscores the
difﬁculties in global prevention and control of HCV by
making an independent reproduction of data obtained
in Western countries necessary for other geographical
areas. The case of Egyptian patients with CHC, in this
sense, is paradigmatic since HCV4 is strikingly
predominant being responsible for over 90% of
chronic infections (Ray et al. 2000). This speciﬁc
Table II. Seroprevalence of ICA in patients with CHC before and
after antiviral treatment.
N (%)
Negative before/negative after treatment 26/40 (65%)
Positive before/positive after treatment 2/40 (5%)
Negative before/positive after treatment 12/40 (30%)
Positive before/negative after treatment 0/40
Figure 1. Detection of serum ICA using indirect immuno-
ﬂuorescence on monkey pancreatic cells. One representative
serum showing a positive pattern indicated by light homogenous
ﬂuorescence in the cytoplasm of pancreatic islet cells is depicted.
Islet cell autoantibodies and interferon-a 13HCV genotype, in fact, has been found to present a
peculiar pattern of progression and response to
treatment (Nguyen and Keeffe 2005).
Autoimmune manifestations can be triggered by
IFNa-based treatment for CHC in a signiﬁcant
proportion of cases (Fattovich et al. 1991, Fattovich
et al. 1996). In particular, autoimmune thyroiditis is
often diagnosed during therapy and is caused by
the development of organ-speciﬁc autoantibodies
(Marcellin et al. 1995). Other endocrine organs are
also possible targets of IFNa-induced autoimmunity.
The de novo appearance of serum antibodies
to pancreatic antigens such as 21-hydroxylase
(an autoantigen of the adrenal cortex), glutamate
decarboxylase 65 (GAD65), or tyrosine phosphatase
(IA2) has been reported in almost 10% of patients
treated with IFNa (Wesche et al. 2001). The latter two
autoantibodies are involved in the pathogenesis of type
1 diabetes. Further, several studies have demonstrated
the development of serum autoantibodies and
sporadic onset of type 1 diabetes in association with
IFNa therapy (Fabris et al. 1998). Lastly, the
appearance of two serum autoantibodies among
ICA, GAD65 and IA2 in patients with CHC being
treated with IFNa led to a considerable risk of
progression to clinically overt diabetes (Wasmuth et al.
2001). An increased independent risk for DM
development associated with chronic HCV infection
was suggested based on clinical observations (Mason
et al. 1999). Interestingly, however, no detectable
GAD65 serum autoantibodies were found in
untreated patients with CHC (Hieronimus et al.
1997), nor endocrine autoimmunity was induced by
IFNa in patients with chronic hepatitis B infection
(Fattovich et al. 1991). Taken altogether, these lines of
evidence indicate that IFNa-based antiviral treatment
and CHC might be necessary but not sufﬁcient
conditions for the induction of pancreatic
autoimmunity.
As discussed above, HCV4 is the most common
genotype involved in Egyptian cases of CHC. Such
genotype has several peculiar characteristics com-
pared to other genotypes. In fact, HCV4 infection
appears to be most commonly secondary to iatrogenic
transmission (Koshy et al. 2000, 2002) while also
presenting a relatively low response rate to both non-
pegylated (el-Zayadi et al. 1996) and pegylated
(Legrand-Abravanel et al. 2005) IFNa. These
observations constitute the bases for the recognized
need of a separate analysis of HCV4 in clinical studies,
commonly underrepresented in larger trials (Manns
et al. 2001, Fried et al. 2002). Based on our data,
however, we submit that the induction of pancreatic
autoimmunity appears to follow a somehow peculiar
pattern in HCV4-infected patients treated with IFNa
compared to other genotypes. First, we report that the
prevalence of serum ICA in untreated patients with
C H Ci sh i g h e rt h a no b s e r v e di no t h e rH C V
genotypes, being 5% (2/40 in our series), but these
cases do not present IGT or DM, similar to previous
reports that included a small proportion of HCV4
(Betterle et al. 2000). Further, we observed that in
both cases such reactivity was still present after IFNa
treatment, thus somehow differing from the titer
increase reported by others (Betterle et al. 2000).
Second, we submit that the appearance of serum ICA
following IFNa treatment should be expected in
approximately one-third of patients with HCV4
chronic infection. The clinical impact of these
autoantibodies, however, appear to be minor since
no case of IGT or DM was found, similar to
observations in other genotypes (Betterle et al. 2000).
In conclusion, we submit that pancreatic-speciﬁc
autoimmunity is not a rare occurrence both before and
after IFNa treatment in Egyptian patients with HCV4
chronic infection. This assumption warrants a further
conﬁrmation based on larger studies on well-deﬁned
middle-eastern patients and the use of pegylated IFNa.
Until these data become available, however, we suggest
thatthescreeningofpatientswithCHCbeforeandafter
antiviral therapy might prove beneﬁcial for the early
diagnosis of pancreatic autoimmune manifestations.
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